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http://dx.doi.org/10.1016/j.kjms.201Abstract Treatment options for patients with castration-resistant prostate cancer (CRPC) are
limited. The purpose of our study was to investigate the safety and efficacy in terms of prostate-
specific antigen (PSA) response of a low-dose oral combination of etoposide and prednisone in
patients with CRPC. Thirty-nine patients with prostate cancer (median age, 77.9 years) with
progressive disease after standard hormonal therapy were enrolled. Etoposide (25 mg, twice
daily) and prednisone (5 mg, twice daily) were administered orally. Each cycle comprised 21
consecutive days of treatment followed by a 7-day drug holiday. All patients previously treated
with an antiandrogen were required to undergo antiandrogen withdrawal prior to entry into
the study. A total of 226 cycles were administered with a median of 6.7 cycles per patient
(range, 1e18 cycles). Sixteen of 39 patients (41%) with elevated PSA levels at baseline achieved
at least a 50% reduction in PSA levels. Median progression-free survival for all patients was 5.9
months (range, 1e17 months). No Grade 4 toxicities were observed. The predominant toxicities
were mucositis, nausea, fatigue, and anemia in twelve, nine, eight, and seven patients, respec-
tively. Hematologic toxicity was infrequent, with no episodes of febrile neutropenia. The com-
bination of low-dose etoposide and prednisone is an efficacious and reasonably well-tolerated
oral regimen in the treatment of elderly patients with CRPC. This regimen can be easily admin-
istered in an outpatient setting and does not require frequent patient visits.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.s have no conflicts of interest relevant to this article.
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Treatment for castration-resistant prostate cancer (CRPC)
is still not established, and CRPC is associated with an
average survival of 12e16 months [1]. In China and other
developing countries, most patients with prostate cancer
present with metastasis and the disease will eventually
progress to CRPC after androgen deprivation for 18e24
months [2]. Docetaxel-based chemotherapy remains the
first-line treatment of choice for CRPC. However, signifi-
cant toxicity, short-lived therapeutic benefit, and heavy
economic burden have led to an understandable skepticism
concerning the use of intravenous chemotherapy. In addi-
tion, many patients with CRPC are unable to reach the
hospital and are unwilling or unfit to be admitted to an
intravenous chemotherapy treatment program. Therefore,
a significant need exists for well-tolerated oral outpatient
treatment regimens.
An oral combination of estramustine phosphate (EMP)
and etoposide has been reported to be effective for CRPC
[3e5]. However, this combination may be associated with
severe side effects such as cardiac complications, leuko-
penia, and deep venous thrombosis [6]. Etoposide is a
semisynthetic derivative of podophyllotoxin, which arrests
the cell cycle at the late S phase [7]. Sensitivity to oral
etoposide has been demonstrated in prostate cancer, lung
cancer, and non-Hodgkin lymphoma [8,9]. In a Phase II
clinical trial for metastatic breast cancer, oral etoposide
monotherapy was effective and well tolerated [10].
Currently, there are few data on oral etoposide in pa-
tients with CRPC. Here, we report the results of a Phase II
trial of a combination of low-dose oral etoposide and
prednisone in elderly patients with CRPC.
Materials and methods
Patient eligibility
Eligible patients were required to have a histologic diag-
nosis of prostate adenocarcinoma with progressive disease
after standard hormonal therapy. All patients previously
treated with antiandrogen therapy were required to un-
dergo antiandrogen withdrawal prior to entry into the
study. Included patients had to have an Eastern Coopera-
tive Oncology Group performance status of 0e2; adequate
renal, hepatic, and hematologic function at baseline; and a
life expectancy of more than 3 months. Patients were
excluded from the study in case of severe uncontrolled
comorbidity, second malignancies, visceral or brain me-
tastases, or previous chemotherapy. All patients were
required to provide written informed consent prior to
enrollment. The ethics review committee of Fudan uni-
versity shanghai cancer center approved the project.
Treatment regimen
Etoposide (25 mg, twice daily) and prednisone (5 mg, twice
daily) were orally administered. Each cycle comprised 21
consecutive days of treatment followed by a 7-day drug
holiday. Therapy was continued until disease progression to
the bone or soft tissue, an increase in the prostate-specificantigen (PSA) level, or occurrence of intolerable toxicity.
Treatment-related toxicity was assessed according to the
National Cancer Institute Common Toxicity Criteria for
Adverse Events version 3.0. Patients requiring more than a
4-week delay in treatment were withdrawn from the study.
If grade 3 or 4 hematologic toxicity was observed during any
cycle, the patient dose was reduced to 75% of the initial
dose for treatment during subsequent weeks. Drug admin-
istration was discontinued in the event of grade 4 non-
hematologic toxicities or grade 3 or worse neurotoxicity.
Evaluation and response
Pretreatment evaluations included taking a complete
medical history, physical examination, chest radiography,
bone scanning, computed tomography (CT) of the abdomen
and pelvis, and laboratory evaluations including a
comprehensive chemistry profile and PSA. Clinical moni-
toring and complete blood cell count assessment were
performed weekly. A full clinical chemistry workup was
performed during each cycle. CT of the abdomen and pelvis
was performed every three cycles. Bone scanning was
performed every 6 months.
PSA levels were measured prior to each cycle every 4
weeks. A decline in the PSA level by >50%, confirmed by a
second evaluation at least 4 weeks later, was considered a
PSA response. PSA progression was defined as a 50% in-
crease over nadir based on two values obtained at least 2
weeks apart if a >50% decline in PSA was noted or a 25%
increase over nadir if a <50% or no decline in PSA was
experienced. Patients who did not meet these criteria of
response and progression were considered to have stable
disease. Lymph node disease was evaluated according to
the Response Evaluation Criteria in Solid Tumors. Disease
progression was defined as PSA progression or appearance
of a new lesion on bone scanning or CT.
Statistical analysis
The PSA response rate and toxicity were the primary end-
points of the study. Progression-free survival (PFS) was the
secondary endpoint, which was calculated from the
beginning of etoposide/prednisone combination therapy to
the time of disease progression. All patients enrolled in the
study were analyzed on an intent-to-treat basis. All statis-
tical analyses were performed using SPSS version 15.0 (SPSS
Inc., Chicago, IL, USA).
Results
Between July 2010 and December 2012, 39 patients were
enrolled into this Phase II study. The characteristics of
these patients are listed in Table 1.
Treatment administered and toxicity
A total of 226 cycles were administered, with a median of
6.7 cycles per patient (range, 1e18 cycles). One patient
discontinued therapy prior to completion of the first cycle
because of Grade 3 fatigue. A total of 3 cycles were delayed
Table 1 Patient characteristics.
No. of patients 39
Eastern Cooperative Oncology Group performance status
0 17 (44)
1 19 (49)
2 3 (8)
Age (y)
Median 77.9
Range 63e87
Osseous disease 27 (69)
Pain 19 (49)
No pain 8( 21)
Lymph node disease 7 (18)
Prostate specific antigen (ng/mL)
Median 69.3
Range 2.7e2364
Prior treatment
Prostatectomy 5 (13)
Radiotherapy 3 (8)
Surgical castration 7 (18)
Medical castration 32 (82)
Second-line hormone therapy 39 (100)
Gleason score
<7 8 (21)
>7 31 (79)
Data are presented as n (%).
84 Y.-P. Zhu et al.for 7e14 days as a result of Grade 2 buccal mucositis in 3
patients. No dose modification was required for the
remaining 36 patients. The predominant toxicities are lis-
ted in Table 2. Hematologic toxicity was infrequent, with
no episodes of febrile neutropenia. No treatment-related
hospitalization was recorded.
Response
Sixteen of 39 patients (41.0%) achieved at least a 50%
reduction in PSA levels, and six patients (15.4%) achieved at
least a 75% reduction in PSA levels. The remaining 23 pa-
tients (58.9%) patients were classified as PSA non-
responders. Nineteen of 27 patients (70.4%) with bone
metastases had bone pain at baseline, and among these 19
patients, symptoms improved in 11 (57.8%), no change was
noted in 5 (26.3%), and worsened bone pain was noted in 3
(15.8%).
During a median follow-up period of 18.1 months (range,
4e35 months), only 5 patients died, and the median overallTable 2 Hematological and nonhematological toxicities.
Toxicity Total Grade 1 Grade 2 Grade 3
Anemia 7 (18) 6 (15) 1 (3) 0 (0)
Leukopenia 5 (13) 4 (10) 1 (3) 0 (0)
Mucositis 12 (31) 9 (23) 3 (8) 0 (0)
Nausea/vomiting 9 (23) 7 (18) 2 (5) 0 (0)
Fatigue 8 (21) 4 (10) 3 (8) 1 (3)
Liver function 4 (10) 3 (8) 1 (3) 0 (0)
Data are presented as n (%).survival has not yet been reached. Median PFS in the overall
series was 5.9 months (range, 1e17 months, Fig. 1). Pa-
tients achieving a PSA response to therapy had a PFS of 8.1
months, which was significantly longer than that of non-
responders (3.7 months, p Z 0.034). No significant differ-
ences in PFS were observed in patients classified according
to baseline PSA levels (>10 vs. <10 ng/mL), and those with
bone pain (relief vs. no relief) or lymph node disease
(response vs. no response; Table 3).
Discussion
Cessation of antiandrogen therapy for at least 4 weeks is
associated with a PSA decrease in 30% of patients who fail
first-line hormonal therapy [11]; however, most patients
without antiandrogen withdrawal syndrome will eventually
receive chemotherapy. Our Phase II trial was designed to
assess the activity, toxicity, and feasibility of an oral low-
dose outpatient regimen of etoposide plus prednisone in
elderly patients with CRPC. In the current study, the eto-
poside dose was reduced to 50 mg/day instead of 50 mg/
m2, considering the median age of 77.9 years of our pa-
tients. Our treatment regimen resulted in a PSA response
rate of 41%, similar to that noted for EMP plus etoposide,
and a median PFS of 5.9 months. In addition, 57.8% of pa-
tients with bone pain experienced symptom improvement.
Toxicity requiring temporary suspension, dose reduc-
tion, and treatment withdrawal has been reported with
other oral chemotherapy regimens, with occurrence rates
ranging from 20% to 40% [4e6]. However, our regimen of
low-dose etoposide plus prednisone resulted in much better
tolerance. A median of 6.7 cycles per patient were
administered, and treatment interruption due to toxicity
was required in only 7.7% of patients. Hematologic toxicity
was infrequent, with no episodes of febrile neutropenia.Figure 1. Progression-free survival of patients included in
the study.
Table 3 Clinical response to treatment.
Response No. of
patients (%)
Median PFS
(mo, range)
p
All patients 39/39 (100) 5.9 (1e17) e
aPSA response 16/39 (41) 8.1 (3e17) 0.034
PSA stable/progression 23/39 (59) 3.7 (1e7) e
Baseline PSA
>10 ng/mL 28/39 (72) 5.8 (1e17) 0.553
<10 ng/mL 11/39 (28) 6.2 (2e13) e
Bone pain 19/39 (49) 6.2 (1e11) e
Relief 11/19 (58) 6.4 (2e11) 0.562
No relief 8/19 (42) 6.0 (1e9) e
Lymph node disease 7/39 (18) 5.1 (1e8) e
CR 0/7 (0) e e
PR 2/7 (29) 5 (4e6) 0.103
SD 4/7 (57) 4.5 (2e6) e
PD 1/7 (14) 1 e
CR Z complete response; PD Z progressive disease;
PFS Z progression free survival; PR Z partial response;
PSA Z prostate-specific antigen; SD Z stable disease.
a PSA decline >50%, confirmed by a second evaluation at least
4 weeks later.
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treatment and monitoring. Thus, this treatment regimen
could be useful for patients in whom geographical, social,
and/or physical difficulties limit access to hospitals for
intravenous chemotherapy or for those otherwise unfit for
combination oral chemotherapy. This treatment can be
safely administered at home for prolonged periods without
significant toxicity and requires minimal monitoring. Our
results showed that patient symptoms and quality of life
improved and PSA response was similar to that achieved
with other full-dose chemotherapeutic regimens, whereas
toxicity was minimized.
A few limitations of this study merit consideration.
Because of the selection criteria in the current study, pa-
tients with visceral metastases and previous chemotherapy
were excluded, which might result in a selection bias.
However, we set these exclusion criteria considering safety
for an elderly patient group (median age, 77.9 years). In
addition, a limited follow-up period prevented us from
drawing any conclusions on overall survival. Kelly et al [12]
found that posttreatment PSA decline was the most
important parameter associated with survival in patients
with CRPC. Therefore, a PSA decrease of more than 50%
from the baseline can serve as a surrogate biologic endpoint
for clinical benefit. Because there is no standard therapy
for patients with CRPC unwilling or unfit to be admitted for
intravenous chemotherapy, no comparison with the stan-
dard therapy could be made in the current study. For
ethical reasons, a placebo control group was not appro-
priate for patients with CRPC.In summary, the combination of low-dose etoposide and
prednisone was an active and reasonably well-tolerated
oral treatment regimen for elderly patients with CRPC. It
can be easily administered in an outpatient setting and
does not require frequent patient visits.Acknowledgments
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